tiprankstipranks
2seventy Bio to discontinue enrollment in Phase 3 KarMMa-9 study of Abecma
PremiumThe Fly2seventy Bio to discontinue enrollment in Phase 3 KarMMa-9 study of Abecma
2M ago
2seventy Bio sees Q3 Abecma U.S. revenue growth ~ 30% vs. Q2
Premium
The Fly
2seventy Bio sees Q3 Abecma U.S. revenue growth ~ 30% vs. Q2
2M ago
2seventy Bio lowers net cash spend range to $40M-60M for FY24
Premium
The Fly
2seventy Bio lowers net cash spend range to $40M-60M for FY24
4M ago
2seventy bio’s Board Elections and Financial Oversight Update
PremiumCompany Announcements2seventy bio’s Board Elections and Financial Oversight Update
5M ago
2seventy Bio downgraded to Sell from Neutral at Goldman Sachs
Premium
The Fly
2seventy Bio downgraded to Sell from Neutral at Goldman Sachs
6M ago
2seventy Bio price target lowered to $11 from $12 at Canaccord
Premium
The Fly
2seventy Bio price target lowered to $11 from $12 at Canaccord
7M ago
Bristol Myers, 2seventy Bio’s Abecma approved by U.S. FDA
PremiumThe FlyBristol Myers, 2seventy Bio’s Abecma approved by U.S. FDA
8M ago
Fly Insider: 2seventy bio, Coinbase among week’s notable insider trades
Premium
The Fly
Fly Insider: 2seventy bio, Coinbase among week’s notable insider trades
8M ago
2seventy bio Finalizes Asset Sale and Executive Transition
Premium
Company Announcements
2seventy bio Finalizes Asset Sale and Executive Transition
8M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100